Potassium homeostasis in patients receiving prophylactic dose enoxaparin therapy.
LetterHuman subjects
Names both Enoxaparin and Potassium in its title.
Supplement × Prescription·Evidence index
PubMed indexes 4 records that name Enoxaparin and Potassium together, either in the title or in an interaction, co-administration, or pharmacokinetic context. Each one is listed below with its study design and, where the abstract states one, the authors’ own conclusion, quoted and linked. This page reports that literature. It does not tell you whether to combine them.
Every statement below is attributed to a named, dated, linked source.
This page lists published research relevant to Enoxaparin and Potassium. It deliberately does not state whether the combination is safe, whether it interacts, in which direction, at what dose, or how far apart to take them.
Strongest relevance first: papers naming both substances in the title, then human trials and systematic reviews.
Names both Enoxaparin and Potassium in its title.
“This study highlights the need to optimize treatments by strictly regulating blood pressure, serum sodium and potassium levels, coagulation parameters and looking for clinical signs of hemorrhage. Physician should be aware of certain drug associations that may carry a risk of severe adverse events.”
Names Enoxaparin and Potassium together in an interaction, co-administration, or pharmacokinetic context.
“Short-term treatment with low-molecular-weight heparin induces a significant increase in serum potassium level but the related incidence of relevant hyperkalemia is low. However, given the high absolute number of patients currently exposed to the risk in many clinical settings and the limitation of risk prediction, clinicians should prevent this life-threatening complication by a high index of suspicion and, accordingly, a quite routine monitoring of serum potassium.”
Names Enoxaparin and Potassium together in an interaction, co-administration, or pharmacokinetic context.
“Practitioners should be aware of the potential for octreotide and heparin to cause hyperkalemia. Regular monitoring of serum potassium concentrations should be done for patients receiving octreotide and heparin to avoid hyperkalemia.”
Names Enoxaparin and Potassium together in an interaction, co-administration, or pharmacokinetic context.
Search-based evidence indexes have real limits, and it is worth being explicit about them:
NutriStack is a free iPhone app for organising a supplement routine: what you take, when, and what the published record says about it. Its exploratory interaction checker covers Enoxaparin, Potassium, and several hundred other substances.
The checker is a research and organisation tool, not a clinical decision aid, and its per-pair assessments are excluded from search until they pass claim-level review.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.